È«º¸¼¾ÅÍ
°øÁö»çÇ×
°Ô½ÃÆÇ ¸®½ºÆ®
ÁÖÁÖ¿©·¯ºÐµé²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2021-01-04
5587
ÁÖÁÖ¿©·¯ºÐµé²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-12-18
4323
ÁÖÁÖ¿©·¯ºÐµé²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-12-17
4902
ÁÖÁÖ¿©·¯ºÐ²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-10-26
6366
ÁÖÁÖ ¿©·¯ºÐ²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-09-22
6959
IR ÀÚ·á (Corporate Overview)
°ü¸®ÀÚ
2020-08-11
6666
¼¼Æ÷Ä¡·áÁ¦ »ý»ê¿ë Á¦2°øÀå ½Ä¾àó Çã°¡
°ü¸®ÀÚ
2020-06-24
5675
°³¹ßÁßÀÎ Á¦Ç° ÁøÇà°èȹ (±¹¹®º»)
°ü¸®ÀÚ
2020-06-24
5257
°³¹ßÁßÀÎ Á¦Ç° ÁøÇà°èȹ
°ü¸®ÀÚ
2020-06-23
4293
ÁÖÁÖ ¿©·¯ºÐ²² ¾Ë·Á µå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-06-17
5303
ÁÖÁÖ ¿©·¯ºÐ²² ¾Ë·Áµå¸³´Ï´Ù
°ü¸®ÀÚ
2020-06-10
4552
302 ÀÓ»ó½ÃÇè Àç°³
°ü¸®ÀÚ
2020-06-09
6361
ALLO-ASC-SheetÀÇ ¹Ì±¹ FDAÀÇ RMAT ÁöÁ¤ÀÇ ÀǹÌ
°ü¸®ÀÚ
2020-05-25
6680
÷´Ü Àç»ýÀÇÇÐ Ä¡·áÁ¦ (Regenerative Medicine Advanced Therapy)¶õ?
°ü¸®ÀÚ
2020-05-25
3655
Company Policy for Expanded Access to Investigational (Unapproved) Drugs
°ü¸®ÀÚ
2020-05-21
4418
´ç´¢º´¼ºÁ·ºÎ±Ë¾çÄ¡·áÁ¦, ¹Ì FDA·ÎºÎÅÍ Ã·´ÜÀç»ýÀÇÇÐÄ¡·áÁ¦(RMAT)·Î ÁöÁ¤½ÂÀÎ
°ü¸®ÀÚ
2020-05-20
4451
Genetic Engineering & Biotechnolgy News º¸µµ³»¿ë
°ü¸®ÀÚ
2020-05-07
3669
ÁÖÁÖ¿©·¯ºÐ²² ¾Ë·Áµå¸³´Ï´Ù.
°ü¸®ÀÚ
2020-04-06
5977
ºÎ±¤¾àǰ º¸À¯ ÁÖ½Ä ÁöºÐÀ² º¯µ¿ °ü·Ã
°ü¸®ÀÚ
2020-03-27
3511
Á¦ 20±â ÁÖÁÖÃÑȸ °ü·Ã ¾È³»»çÇ×
°ü¸®ÀÚ
2020-03-18
2291
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
Á¦¸ñ
³»¿ë
±Û¾´ÀÌ
´Ý±â
.
¾ÈÆ®·ÎÁ¨(º»»ç ¹× ÀǾàǰ Á¦Á¶¼Ò) : (08589) ¼¿ïƯº°½Ã ±Ýõ±¸ °¡»êµ¿ 345-30
¾ÈÆ®·ÎÁ¨(Áß¾Ó¿¬±¸¼Ò) : (07805) ¼¿ïƯº°½Ã °¼±¸ ¹ß»ê1µ¿ ¸¶°îÁß¾Ó2·Î 65 / ÀüȹøÈ£: 02-2104-0391~0392
COPYRIGHT (C) 2012 ANTEROGEN.CO.,LTD. ALL RIGHTS RESERVED.